The Ganesha Lab
VC Fund
Santiago, Chile
The Ganesha Lab is a Global Biotech Scale up for science and technology-based startups in Latam. We aim to inspire a better understanding of culture and responsiveness of evolving humans, connecting the world of science, biotech, entrepreneurs and people.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries The Ganesha Lab invests in
Stages The Ganesha Lab invests in
Countries The Ganesha Lab invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Diego Belmar
|
|||
Investment Focus
Industry
- Biotechnology 5 (21%)
- Apps 1 (4%)
- Farming 1 (4%)
- Fashion 1 (4%)
- Chemical 1 (4%)
Stage
- Non-equity Assistance 5 (21%)
- Seed 1 (4%)
Country
- Chile 2 (8%)
- United States 2 (8%)
- Uruguay 1 (4%)
- Argentina 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Diego Belmar
Portfolio Manager
|
Portfolio Manager | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Amplify Dynamics
|
Amplify Dynamics is a biotechnology firm that offers modern purification methods for lipid nanoparticles. | Non-equity Assistance / Jan 01, 2024 | |
Dyegon
|
Dyegon produces natural pigments using Patagonian bacteria's natural properties, which are used in the fashion industry. | Non-equity Assistance / Jan 01, 2024 | |
Nanotransfer
|
Nanotransfer develops delivery systems, based on inorganic nanoparticles, with several benefits: Ready-to-use: clients just have to produce the genetic material and choose a suitable Nanotransfer system to integrate it with the gene. Versatility: they can be used to transport different types of nucleic acids. Biosafety: they are non immunogenic,any patient can be elegible and re-administration is possible. Specificity: They can be specific for a cell type. Scalable and low-cost production. High levels of cellular internalization. Nanotransfer delivery systems have a chemical affinity for the phosphate backbone, common to all nucleic acids, so the integration of the gene with the delivery system is independent of its sequence. We can decouple the synthesis of the delivery system and that of the geneof interest, which will allow a greater number of therapies to be developed with a positive impact on people´s health. Our non-viral delivery systems are unique not only because they are non-toxic and non-immunogenic but also becasue of their composition and surface properties. Due to their composition, our delivery systems can escape the endosome and avoid enzyme degradation. The surface properties can be tailored to target specific cells. | Non-equity Assistance / Jan 01, 2024 | |
EYWA
|
EYWA designs the best processes and products to boost the adoption of psychedelic medicine, harnessing the power of biosynthesis. | Non-equity Assistance / Jan 01, 2024 | |
Tell
|
Tell provides natural speech metrics for fast, objective insights on neurocognition. | Non-equity Assistance / Jan 01, 2024 | |
Aquit
|
Aquit develops preventive treatments for infections in fish that replace antibiotics, improve survival rates, and boost natural immunity. | Pre-Seed / Apr 11, 2023 | |
Biogea
|
Biogea offers agricultural solutions that help in increasing yield. | Seed / Jan 01, 2023 | |
Innovai
|
Innovai is a food tech platform focused on improving the shelf-life and quality of seafood. | Seed / Jan 01, 2023 | |
Delee
|
Delee is a medical device company that aims to revolutionize how cancer is diagnosed and managed. That is why we developed CytoCatch™, a patent-pending technology that enables the performance of a CTC blood-based assay that has the potential of being used for early cancer detection and monitoring of the applied treatments’ effectiveness.Thistechnology consists of an isolation platform, which automatically performs the necessary steps to process the sample, capturing the CTCs contained in it, and an imaging system, which possesses special routines and machine learning algorithms that analyze the captured cells based on their morphology and the expression of specific markers. The fact that all these processes are fully automated increases the reliability and reproducibility of the assay by preventing human errors and cell loss due to manual steps. Furthermore, the collected cells are compatible with traditional molecular biology techniques and next-generation technologies, enabling the performance of molecular analysis to assess the genetic characteristics of the captured CTCs. This innovative technology will enable a broad range of cancer-related clinical applications. | Seed / Jan 01, 2023 | |
Trears Biomarkers
|
Trears Biomarkers develop earwax self-sampling device to measure long-term levels of several chronic diseases. | Venture - Series Unknown / Jan 01, 2023 | |
| See all 24 investments → | |||
Co-Investors
3IE
1 deal together
El Viento
1 deal together
GRID EXPONENTIAL
1 deal together
International Development Bank
1 deal together
Magical
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does The Ganesha Lab invest in?
The Ganesha Lab invests primarily in Biotechnology, Apps and Farming startups, most often at Non-equity Assistance and Seed stage. Most of the 24 investments tracked by Shizune back companies in Chile. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact The Ganesha Lab?
Public channels for The Ganesha Lab include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at The Ganesha Lab?
The team at The Ganesha Lab includes Diego Belmar (Portfolio Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
